Answers are grounded in this paper and cite their sources.
Late-stage labeling with fluorine-18 serves to advance clinical care and drug discovery via positron emission tomography (PET). This goal motivates efforts to expand the accessible chemical space with tailored 18F-containing groups. Sulfamoyl fluorides are promising because of their potential physiological stability. Existing synthetic routes largely depend on group-transfer protocols from preformed fluorosulfonyl reagents. As a result, synthetic methods for [18F]sulfamoyl fluorides are fundamentally based on isotope exchange. None of the methods have enabled a no-carrier-added (NCA) protocol for radiofluorosulfonylation of amines. Herein, we provide nitrogen-centered radical-mediated assembling fluorosulfonylation reactions, enabling conversion of abundant NH-containing substrates into sulfamoyl fluorides with [19F]fluoride and [18F]fluoride as an exclusive fluorine source. Our method features high functional group tolerance, broad NH-substrates, and an NCA radiochemical technique. The initial preclinical evaluation of the freshly synthesized [18F]SUFA-flurpiridaz and its in vivo myocardial perfusion PET imaging collectively highlights the potential physiological stability of sulfamoyl [18F]fluoride groups and the potential application of our radical radiofluorosulfonylation strategy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: